Invesco Ltd. lowered its stake in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 7.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 378,880 shares of the company's stock after selling 28,325 shares during the quarter. Invesco Ltd. owned about 0.13% of Lyell Immunopharma worth $204,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. Exchange Traded Concepts LLC grew its position in Lyell Immunopharma by 82.4% during the first quarter. Exchange Traded Concepts LLC now owns 246,349 shares of the company's stock worth $133,000 after buying an additional 111,299 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in Lyell Immunopharma during the fourth quarter worth $64,000. venBio Partners LLC bought a new stake in Lyell Immunopharma during the fourth quarter worth $4,545,000. Two Sigma Advisers LP lifted its stake in Lyell Immunopharma by 143.8% during the fourth quarter. Two Sigma Advisers LP now owns 306,400 shares of the company's stock worth $196,000 after purchasing an additional 180,700 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Lyell Immunopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company's stock worth $613,000 after purchasing an additional 247,440 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on LYEL shares. HC Wainwright restated a "neutral" rating and set a $10.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, June 24th. Wall Street Zen upgraded Lyell Immunopharma from a "sell" rating to a "hold" rating in a research note on Monday, September 1st. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Reduce" and a consensus target price of $15.00.
Get Our Latest Analysis on LYEL
Lyell Immunopharma Stock Performance
Shares of LYEL opened at $13.03 on Tuesday. Lyell Immunopharma, Inc. has a 52 week low of $7.65 and a 52 week high of $32.00. The stock has a market capitalization of $250.31 million, a price-to-earnings ratio of -0.54 and a beta of -0.19. The stock has a fifty day moving average of $10.76 and a 200-day moving average of $10.33.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.
Lyell Immunopharma Company Profile
(
Free Report)
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
See Also
Want to see what other hedge funds are holding LYEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
